BioStratum Incorporated Elects Harry H. Penner to Board of Directors

-- Neurogen President and CEO Brings Wide Experience in Biotech and

Pharmaceutical Industries, Diabetes Market --



Apr 18, 2001, 01:00 ET from BioStratum Incorporated

    RESEARCH TRIANGLE PARK, N.C., April 18 /PRNewswire/ --BioStratum
 Incorporated, a worldwide leader in drug development based on basal lamina
 research, announced today the election of Harry H. Penner, Neurogen President
 and CEO, to the Company's Board of Directors.
     "Harry has extensive experience both with growing biotech companies and
 major pharmaceutical firms," said Dr. Claus Kuhl, BioStratum President and
 CEO.  "His deep knowledge of the market for treating diabetes and related
 diseases is especially important to us now as we move Pyridorin(TM), our lead
 drug candidate targeted at treating diabetic kidney disease, through clinical
 trials and toward product commercialization."
     For nearly 25 years, Mr. Penner has been leading biotech and
 pharmaceutical companies through corporate alliances, acquisitions, large
 financial offerings, and product portfolio growth.   Under his leadership,
 Neurogen became a broadly based, well-financed biotech company.  Prior to
 leading Neurogen, Mr. Penner was an executive with Novo Nordisk A/S, a
 diabetes care company.  He also serves on the boards of directors of Avant
 Immunotherapeutics Inc., Genaissance Pharmaceuticals Inc., Packard BioScience
 Company, and PRA International Inc.
     "BioStratum is an exciting, promising biotech company," said Mr. Penner.
 "Its premier basal lamina research capabilities and experience give it a
 unique science platform from which it is developing a pipeline of innovative
 therapies.  Pyridorin(TM), the Company's lead drug candidate, has the
 potential to break new ground in treating diabetic kidney disease.  It
 promises high therapeutic value for patients worldwide and a major commercial
 opportunity for BioStratum."
 
     About BioStratum
     Biostratum, a world leader in basal lamina research, is developing a
 pipeline of drugs based on research on the basal lamina's central role in many
 diseases.  The Company's lead drug candidate, Pyridorin(TM), is currently
 advancing through clinical trials for diabetic kidney disease. BioStratum is
 working to have Angiocol(TM) -- its proprietary anti-angiogenesis drug
 candidate that dramatically inhibits the growth of tumors in animal models of
 cancer -- enter clinical trials in late 2001.  BioStratum is also developing
 novel therapeutics for other kidney diseases, tissue regeneration, and
 autoimmune diseases. Headquartered in Research Triangle Park, North Carolina,
 BioStratum's research and development operations are further extended through
 multiple collaborations with leading basal lamina research centers.  For
 further information, please visit www.biostratum.com.
 
      CONTACT:
      BioStratum Incorporated
      Mike Klodnicki
      Director of Investor Relations and
      Corporate Communications
      (919) 474-7112
       mklodnicki@BioStratum.com
 
      Feinstein Kean Healthcare
      Harriet Ullman
      (617) 577-8110
      hullman@fkhealth.com
 
 

SOURCE BioStratum Incorporated
    RESEARCH TRIANGLE PARK, N.C., April 18 /PRNewswire/ --BioStratum
 Incorporated, a worldwide leader in drug development based on basal lamina
 research, announced today the election of Harry H. Penner, Neurogen President
 and CEO, to the Company's Board of Directors.
     "Harry has extensive experience both with growing biotech companies and
 major pharmaceutical firms," said Dr. Claus Kuhl, BioStratum President and
 CEO.  "His deep knowledge of the market for treating diabetes and related
 diseases is especially important to us now as we move Pyridorin(TM), our lead
 drug candidate targeted at treating diabetic kidney disease, through clinical
 trials and toward product commercialization."
     For nearly 25 years, Mr. Penner has been leading biotech and
 pharmaceutical companies through corporate alliances, acquisitions, large
 financial offerings, and product portfolio growth.   Under his leadership,
 Neurogen became a broadly based, well-financed biotech company.  Prior to
 leading Neurogen, Mr. Penner was an executive with Novo Nordisk A/S, a
 diabetes care company.  He also serves on the boards of directors of Avant
 Immunotherapeutics Inc., Genaissance Pharmaceuticals Inc., Packard BioScience
 Company, and PRA International Inc.
     "BioStratum is an exciting, promising biotech company," said Mr. Penner.
 "Its premier basal lamina research capabilities and experience give it a
 unique science platform from which it is developing a pipeline of innovative
 therapies.  Pyridorin(TM), the Company's lead drug candidate, has the
 potential to break new ground in treating diabetic kidney disease.  It
 promises high therapeutic value for patients worldwide and a major commercial
 opportunity for BioStratum."
 
     About BioStratum
     Biostratum, a world leader in basal lamina research, is developing a
 pipeline of drugs based on research on the basal lamina's central role in many
 diseases.  The Company's lead drug candidate, Pyridorin(TM), is currently
 advancing through clinical trials for diabetic kidney disease. BioStratum is
 working to have Angiocol(TM) -- its proprietary anti-angiogenesis drug
 candidate that dramatically inhibits the growth of tumors in animal models of
 cancer -- enter clinical trials in late 2001.  BioStratum is also developing
 novel therapeutics for other kidney diseases, tissue regeneration, and
 autoimmune diseases. Headquartered in Research Triangle Park, North Carolina,
 BioStratum's research and development operations are further extended through
 multiple collaborations with leading basal lamina research centers.  For
 further information, please visit www.biostratum.com.
 
      CONTACT:
      BioStratum Incorporated
      Mike Klodnicki
      Director of Investor Relations and
      Corporate Communications
      (919) 474-7112
       mklodnicki@BioStratum.com
 
      Feinstein Kean Healthcare
      Harriet Ullman
      (617) 577-8110
      hullman@fkhealth.com
 
 SOURCE  BioStratum Incorporated